Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer (Investigational New Drugs, (2018), 10.1007/s10637-018-0663-0)

Laura W. Goff, Nilofer S. Azad, Stacey Stein, Jennifer G. Whisenant, Tatsuki Koyama, Ulka Vaishampayan, Howard Hochster, Roisin Connolly, Amy Weise, Patricia M. LoRusso, Safia N. Salaria, Wael El-Rifai, Jordan D. Berlin

Research output: Contribution to journalComment/debate

Abstract

The authors would like to note that the investigator affiliations have been corrected to reflect the actual affiliations of each author. The authors would also like to note an amendment to the first name of the second author. Nilo Azad was changed to reflect the full name of the author, which is Nilofer S. Azad as shown above. The original article has been corrected.

Original languageEnglish (US)
Number of pages1
JournalInvestigational New Drugs
Volume36
Issue number6
DOIs
StatePublished - Dec 1 2018

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer (Investigational New Drugs, (2018), 10.1007/s10637-018-0663-0)'. Together they form a unique fingerprint.

  • Cite this

    Goff, L. W., Azad, N. S., Stein, S., Whisenant, J. G., Koyama, T., Vaishampayan, U., Hochster, H., Connolly, R., Weise, A., LoRusso, P. M., Salaria, S. N., El-Rifai, W., & Berlin, J. D. (2018). Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer (Investigational New Drugs, (2018), 10.1007/s10637-018-0663-0). Investigational New Drugs, 36(6). https://doi.org/10.1007/s10637-018-0679-5